Skip to Main Content
Table 2

Antitumor activities of bortezomib in solid tumor models

CellsAnimal model and dosing scheduleAntitumor activity
Human prostate cancer, PC-3 (11) Athymic nude mice, weekly ×4 60% decrease in tumor volume 
Human MIA-PACa-2 pancreatic cancer (10) Athymic nude mice, twice weekly ×3.5 75% growth inhibition with combination with bortezomib and gemcitabine versus 59% growth inhibition with gemcitabine alone 
Human pancreatic cancer, BxPc-3 (15) Athymic nude mice, weekly ×4 89% growth inhibition with combination bortezomib and CPT-11 versus 43% with CPT-11 alone 
Human LOVO colon cancer (14) Athymic nude mice, twice weekly 94% decrease in tumor size with combination bortezomib and CPT-11 versus 48% with CPT-11 alone 
Human LOVO colon cancer (90) Athymic nude mice, 6 h before irradiation 7–41% increase in radiosensitivity with bortezomib leading to an 84% reduction in tumor volume 
Squamous cell carcinoma: murine PAM-LY2 (91) Balb/C SCID mice, three times weekly 50–80% dose-dependent decrease in tumor volume 
Murine lung cancer and human breast cancer (92) Lewis lung model, EMT-6 mouse model; daily treatment Lewis lung model: growth delay and decreased number of lung metastases alone and in combination (5-fluorouracil, cisplatin, paclitaxel, or docetaxel); EMT-6: dose-dependent cytotoxicity alone and potentiated tumor cell killing with cyclophosphamide, allowing dose reduction 
CellsAnimal model and dosing scheduleAntitumor activity
Human prostate cancer, PC-3 (11) Athymic nude mice, weekly ×4 60% decrease in tumor volume 
Human MIA-PACa-2 pancreatic cancer (10) Athymic nude mice, twice weekly ×3.5 75% growth inhibition with combination with bortezomib and gemcitabine versus 59% growth inhibition with gemcitabine alone 
Human pancreatic cancer, BxPc-3 (15) Athymic nude mice, weekly ×4 89% growth inhibition with combination bortezomib and CPT-11 versus 43% with CPT-11 alone 
Human LOVO colon cancer (14) Athymic nude mice, twice weekly 94% decrease in tumor size with combination bortezomib and CPT-11 versus 48% with CPT-11 alone 
Human LOVO colon cancer (90) Athymic nude mice, 6 h before irradiation 7–41% increase in radiosensitivity with bortezomib leading to an 84% reduction in tumor volume 
Squamous cell carcinoma: murine PAM-LY2 (91) Balb/C SCID mice, three times weekly 50–80% dose-dependent decrease in tumor volume 
Murine lung cancer and human breast cancer (92) Lewis lung model, EMT-6 mouse model; daily treatment Lewis lung model: growth delay and decreased number of lung metastases alone and in combination (5-fluorouracil, cisplatin, paclitaxel, or docetaxel); EMT-6: dose-dependent cytotoxicity alone and potentiated tumor cell killing with cyclophosphamide, allowing dose reduction 
Close Modal

or Create an Account

Close Modal
Close Modal